Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1194 of 6351
-
App-Based treatment shows promise for alcohol addiction
Disease control CompletedThis study is a two-arm randomized clinical trial comparing the Quit Genius intervention for alcohol use disorder (QG-A) to usual care (TAU), comprising medical management of alcohol use disorders with pharmacotherapy. Participants (N=300) will be randomly assigned to either QG-A…
Phase 2/3 • Sponsor: Quit Genius • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New weekly shot could help control blood sugar in type 2 diabetes
Disease control CompletedThe main purpose of this study is to investigate the efficacy and safety of XW003 versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise alone
Phase 3 • Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:54 UTC
-
New eye drops could replace reading glasses for millions
Symptom relief CompletedThe objectives of this study are: To evaluate the safety and efficacy of Nyxol alone and with adjunctive low dose pilocarpine to improve distance-corrected near visual acuity (DCNVA) in subjects with presbyopia.
Phase 3 • Sponsor: Ocuphire Pharma, Inc. • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Blood test could unmask silent heart failure in diabetics
Diagnosis OngoingThis is a prospective, multicentre, unblinded, randomised, controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients with diabetes.
Sponsor: NHS Greater Glasgow and Clyde • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
Magnetic pulses aim to lift depression in bipolar II
Disease control OngoingThe purpose of this study is to investigate the effectiveness of accelerated intermittent theta-burst transcranial magnetic stimulation (aiTBS) in inducing anti-depressant responses in individuals with treatment-resistant depression of bipolar II disorder. This is a double-blind,…
Sponsor: Stanford University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New study tests repatha® combo to slash heart risks in 7,000 chinese patients
Disease control OngoingThe primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary …
Sponsor: Amgen • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New study aims to predict lung cancer in Never-Smokers
Knowledge-focused Recruiting nowLung Cancer is the leading cause of cancer-related deaths in Taiwan and worldwide and the incidence is also increasing. The payment for lung cancer which occupies the largest part of National Health Insurance expense is over 15 billion in 2018. Because about 80% lung cancer patie…
Sponsor: Chung Shan Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Heart drug mavacamten tested in Non-Obstructive HCM trial
Symptom relief CompletedThe purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
New device could stop bedsores before they start in nursing homes
Prevention OngoingPressure injuries, local areas of damage to the skin and underlying soft tissue that are costly and painful, are often preventable with timely use of prevention strategies. Identifying early pressure induced tissue damage among nursing home residents by nursing staff during routi…
Phase 2 • Sponsor: University of California, Los Angeles • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Could CBD ease the grip of PTSD? new trial investigates
Symptom relief Recruiting nowPost-traumatic stress disorder (PTSD) is a psychiatric disorder than may develop following a traumatic event including serious incidents, natural or human-caused disasters, violence, death of a loved one, receipt of traumatic news, or serious illness/hospitalization. While half o…
Phase 2 • Sponsor: University of Nebraska • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Aerosol chemo shows promise for Hard-to-Treat stomach cancer
Disease control CompletedPeritoneum is among the most common sites of metastases in gastric cancer. Systemic chemotherapy is the current standard for peritoneal carcinomatosis (PC), although, the treatment results remain extremely poor. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a modern…
Sponsor: Vilnius University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could an old arthritis pill keep brain arteries open and prevent stroke?
Disease control Recruiting nowIntracranial atherosclerotic disease (ICAD) is a major ischaemic stroke aetiology in Asia. Influenced by genetics, lifestyle and metabolic risk factors. From the SAMMPRIS cohort, 1-year stroke recurrence risk was 13% even with intensive medical therapy. In this pilot randomized,…
Phase 2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Genetic test may spare thousands of women from unnecessary radiation
Disease control Recruiting nowTo evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Supercharged immune cells take on tough melanoma
Disease control CompletedThe purpose of this first in human study is to evaluate the feasibility, safety, and efficacy of administering TBio-4101 (tumor infiltrating lymphocytes \[TIL\]) after receiving a lymphodepleting chemotherapy regimen and before receiving interleukin-2 (IL-2) in participants with …
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug targets wasting syndrome in cancer patients
Symptom relief CompletedStudy to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
Phase 2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Saving the ligament: a trial tests whether repairing a torn ACL beats replacing it
Disease control Recruiting nowBackground: Arthroscopic anterior cruciate ligament(ACL) reconstruction is so far the gold standard for the treatment of ACL ruptures, but this technique still suffers from problems of tendon-bone healing, bone tunnel enlargement, bone resorption, a low rate of return to motion,e…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New 6-Month shot shows promise for prostate cancer control
Disease control CompletedThe main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulat…
Phase 3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 26, 2026 14:39 UTC
-
Could a pacemaker boost exercise capacity in adults with a rare heart condition?
Disease control CompletedThe main objective of RIGHT-CRT is to assess the impact/efficacy of CRT on functional capacity in ACHD patients with SRV.
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New depression drug shows promise in large trial
Symptom relief CompletedDemonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \& CGI-S) in MDD patients who had an inadequate response to prior ADT therapy.
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
New shot could tame stubborn high blood pressure
Disease control CompletedThe purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC) injections, compared to placebo. Since all study particip…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC